**Amended Claims:**

CLAIMS

1. (Currently Amended)A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ~~i~~, ii, ~~iii, or iv~~



ii

B is

(a)  ,

(b)  , or

(c)  ;

W is $NHC(=X)R_1$, or -Y-het; X is O, or S; provided that when X is O, B is not the subsection (b);

Y is NH, O, or S;

Z is $S(=O)(=N-R_5)$;

$R_1$ is

(a) H,

(b) $NH_2$,

(c) $NHC_{1-4}$alkyl,

(d) $C_{1-4}$alkyl,

(e) $C_{2-4}$alkenyl,

(f) $OC_{1-4}$alkyl,

(g) $SC_{1-4}$alkyl, or

(h) $(CH_2)_p C_{3-6}$cycloalkyl;

at each occurrence, alkyl or cycloalkyl in $R_1$ is optionally substituted with one or more F, Cl or CN;

$R_2$ and $R_3$ are independently H, F, Cl, methyl or ethyl;

$R_4$ is H, $CH_3$, or F;

$R_5$ is

(c) $C(=O)C_{1-4}$alkyl,

(d) $C(=O)OC_{1-4}$alkyl,

(e) $C(=O)NHR_6$, or

(f) $C(=S)NHR_6$;

$R_6$ is H, $C_{1-4}$alkyl, or phenyl;
at each occurrence, alkyl in $R_5$ and $R_6$ is optionally substituted with one or more halo, CN, $NO_2$, phenyl, $C_{3-6}$ cycloalkyl, $OR_7$, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, $NR_7R_7$, oxo, or oxime;

$R_7$ is H, $C_{1-4}$alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, $CF_3$, CH3, CN, $NO_2$, phenyl, $C_{3-6}$ cycloalkyl, $OR_7$, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, or $NR_7R_7$;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2; and

n is 2 or 3

2. A compound of claim 1 having the formula IA:



IA.

3. A compound of claim 2 wherein $R_1$ is $C_{1-4}$alkyl.

4. A compound of claim 2 wherein $R_1$ is ethyl.

5. A compound of claim 2 wherein $R_1$ is methyl.

6. A compound of claim 2 wherein $R_1$ is $C_{3-6}$cycloalkyl.

7. A compound of claim 2 wherein $R_1$ is cyclopropyl.

8. A compound of claim 2-7 wherein X is sulfur atom.

9. A compound of claim 2-7 wherein X oxygen atom.

10. A compound of claim 8 wherein one of $R_2$ and $R_3$ is H, the other one is F.

11. A compound of claim 9 wherein one of $R_2$ and $R_3$ is H, the other one is F.

12. A compound of claim 8 wherein $R_4$ is H.

13. A compound of claim 9 wherein $R_4$ is H.

14. A compound of claim 8 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

16. A compound of claim 8 wherein structure B is



wherein Z is $S(=O)(=NR_5)$

17. A compound of claim 9 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

22. A compound of claim 14 wherein $R_5$ is $C(=O)C_{1\text{-}4}$alkyl, $C(=O)OC_{1\text{-}4}$alkyl, $C(=O)NH_2$, or $C(=O)NHC_{1\text{-}4}$alkyl.

23. A compound of claim 22 wherein $R_5$ is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

24. A compound of claim 14 wherein $R_5$ is $C(=O)CH_3$.

25. A compound of claim 14 wherein $R_5$ is $C(=O)OCH_3$.

30. A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of formula I as shown in claim 1.

31. The method of claim 30 wherein said compound of formula I is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.

32. The method of claim 30 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

33. The method of claim 30 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

34. A method for treating microbial infections of claim 30 wherein the infection is skin infection.

35. A method for treating microbial infections of claim 30 wherein the infection is eye infection.

36. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

38. A compound of claim 16 wherein $R_5$ is $C(=O)C_{1-4}$alkyl, $C(=O)OC_{1-4}$alkyl, $C(=O)NH_2$, or $C(=O)NHC_{1-4}$alkyl.

39. A compound of claim 38 wherein $R_5$ is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

40. A compound of claim 16 wherein $R_5$ is $C(=O)CH_3$.

41. A compound of claim 16 wherein $R_5$ is $C(=O)OCH_3$.

42. A compound of claim 17 wherein $R_5$ is $C(=O)C_{1-4}$alkyl, $C(=O)OC_{1-4}$alkyl, $C(=O)NH_2$, or $C(=O)NHC_{1-4}$alkyl.

43. A compound of claim 42 wherein $R_5$ is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

44. A compound of claim 17 wherein $R_5$ is $C(=O)CH_3$.

45. A compound of claim 17 wherein $R_5$ is $C(=O)OCH_3$.

46. (Currently amended) A compound of claim 2 which is

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-{[(methylamino)carbonyl]imino}-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

~~N-({(5*S*)-3-[3-fluoro-4-(1-[[(ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;~~

N-({(5*S*)-3-[3-fluoro-4-(1-{[[(4-nitrophenyl)amino]carbonyl]imino}-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer ;

N-({(5*S*)-3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

~~N-({(5*S*)-3-[3-fluoro-4-[1-[[(aminocarbonyl)methyl]imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;~~

N-[((5*S*)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1$\lambda^4$, 4-thiazinan-4-yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanethioamide;

N-[((5*S*)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1$\lambda^4$, 4-thiazinan-4-yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarbothioamide ;

N-[((5*S*)-3-{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5- yl)methyl] cyclopropanecarbothioamide, *Z*-isomer;

N-[((5*S*)-3-{3-fluoro-4-[1-[[(phenylmethoxy)carbonyl]imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide, *Z*-isomer; or

N-({(5*S*)-3-[3-fluoro-4-(1-{[(benzylamino)carbonyl]imino}-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, *Z*-isomer.

47. (Currently amended)1. A compound of formula II



II

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ii



ii ;

B is



;

W is NHC(=X)$R_1$, or -Y-het;

X is O, or S;

Y is NH, O, or S;

Z is S(=O)(=N-$R_5$) and the B ring has the following stereochemistry




;




;

$R_1$ is

(a) H,

(b) $NH_2$,

(c) $NHC_{1-4}$alkyl,

(d) $C_{1-4}$alkyl,

(e) $C_{2-4}$alkenyl,

(f) $OC_{1-4}$alkyl,

(g) $SC_{1-4}$alkyl, or

(h) $(CH_2)_p C_{3-6}$cycloalkyl;

at each occurrence, alkyl or cycloalkyl in $R_1$ is optionally substituted with one or more F, Cl or CN;

$R_2$ and $R_3$ are independently H, F, Cl, methyl or ethyl;

$R_4$ is H, $CH_3$, or F;

$R_5$ is

(a) H,

(b) $C_{1-4}$alkyl,

(c) $C(=O)C_{1-4}$alkyl,

(d) $C(=O)OC_{1-4}$alkyl,

(e) $C(=O)NHR_6$, or

(f) $C(=S)NHR_6$;

$R_6$ is H, $C_{1-4}$alkyl, or phenyl;
at each occurrence, alkyl in $R_5$ and $R_6$ is optionally substituted with one or more halo, CN, $NO_2$, phenyl, $C_{3-6}$ cycloalkyl, $OR_7$, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, $NR_7R_7$, oxo, or oxime;

$R_7$ is H, $C_{1-4}$alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, $CF_3$ CH3, CN, $NO_2$, phenyl, $C_{3-6}$ cycloalkyl, $OR_7$, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, or $NR_7R_7$;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2;

and ----- in structure iii is either a double bond or a single bond..

48. The compound of claim 47 wherein $R_1$ is $C_{1-4}$alkyl.

49. The compound of claim 47 wherein $R_1$ is ethyl.

50. The compound of claim 47 wherein $R_1$ is methyl.

51. The compound of claim 47 wherein $R_1$ is $C_{3-6}$cycloalkyl.

52. The compound of claim 47 wherein $R_1$ is cyclopropyl.

53. The compound of claim 47 wherein X is sulfur atom.

54. The compound of claim 47 wherein X oxygen atom.

55. The compound of claim 53 wherein one of $R_2$ and $R_3$ is H, the other one is F.

56. The compound of claim 54 wherein one of $R_2$ and $R_3$ is H, the other one is F.

57. The compound of claim 47 wherein $R_5$ is H.

58. The compound of claim 47 wherein $R_5$ is $C_{1-4}$alkyl, optionally substituted with OH; or $C_{1-4}$alkyl substituted with $C(=O)NHC_{1-4}$alkyl, $C(=O)NH_2$ or phenyl; wherein the phenyl is optionally substituted with OH, methyl, $NO_2$, $CF_3$, or CN.

59. The compound of claim 47 wherein $R_5$ is $CH_3$, or ethyl.

60. The compound of claim 47 wherein $R_5$ is $C_{1-4}$alkyl substituted with phenyl wherein the phenyl is optionally substituted with $NO_2$.

61. The compound of claim 47 wherein $R_5$ is $C(=O)C_{1-4}$alkyl, $C(=O)OC_{1-4}$alkyl, $C(=O)NH_2$, or $C(=O)NHC_{1-4}$alkyl.

62. The compound of claim 47 wherein $R_5$ is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

63. The compound of claim 47 wherein $R_5$ is $C(=O)CH_3$.

64. The compound of claim 47 wherein $R_5$ is $C(=O)OCH_3$.

65. A compound of claim 47 which is
N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide (Z)-isomer;
N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide (Z)-isomer;
N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide (Z)-isomer;
N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)cyclopropanethioamide (Z)-isomer;
N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, Z-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(ethylimino)-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-[(phenylmethyl)imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-[(3-phenylpropyl)imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-{[(methylamino)carbonyl]imino}-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-[[(ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-{[[(4-nitrophenyl)amino]carbonyl]imino}-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer ;

N-({(5*S*)-3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-[[(aminocarbonyl)methyl]imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-[(2-hydroxyethyl)imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)cyclopropanecarbothioamide, *Z*-isomer;

N-[((5*S*)-3-{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1$\lambda^4$-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarbothioamide, *Z*-isomer;